skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

13th C1-inhibitor deficiency and angioedema workshop--2023

Allergy, asthma, and clinical immunology, 2023-12, Vol.19 (Suppl 1), p.1-46 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1710-1492 ;ISSN: 1710-1484 ;EISSN: 1710-1492 ;DOI: 10.1186/s13223-023-00845-9

Full text available

Citations Cited by
  • Title:
    13th C1-inhibitor deficiency and angioedema workshop--2023
  • Subjects: Angioedema ; Angioneurotic edema ; Asthma ; B cells ; Biotechnology industry ; Bradykinin ; Conferences ; Conferences, meetings and seminars ; CRISPR ; Development and progression ; Disease prevention ; Ethylenediaminetetraacetic acid ; Heparan sulfate ; Immunology ; Medical research ; Monoclonal antibodies ; Mutation ; Pathogenesis ; Patients ; Peptides ; Pharmaceutical industry ; Plasma ; Tranexamic acid ; Workshops (Educational programs)
  • Is Part Of: Allergy, asthma, and clinical immunology, 2023-12, Vol.19 (Suppl 1), p.1-46
  • Description: In 2023, the 13th edition of the biennial international scientific conference on C1-inhibitor deficiency and other bradykinin-mediated angioedema took place from 4 to 7 May. Since 1999, when the Workshop was held for the first time, the composition of the registrants has been unique, with active and equal participation in the scientific discussions from allergists, immunologists, dermatologists, otorhinolaryngologists, internists, paediatricians and other specialists, as well as from research biologists, biochemists and pharmaceutical researchers, and representatives of the patient organisations involved in the disease. Preliminary data of an oral B-2 receptor antagonist with a deuterium atom incorporated has a long half-life of 10 h., inhibits intravenous bradykinin effects including decreased blood pressure within 15 min. and lasts 8 h. In a phase 2, dose ranging study, HAE attacks were successfully treated. [...]there was attention to classification of the many types of angioedema. Currently, 6 types of HAEnCI are recognized, based on underlying mutations of factor XII (HAE-FXII), angiopoietin-1 (HAE-ANGPT1), plasminogen (HAE-PLG, Hereditary Angioedema with the plasminogen gene mutation K330E), kininogen 1 (HAE-KNG1), myoferlin (HAE-MYOF), and heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HAE-HS3ST6).
  • Publisher: London: BioMed Central Ltd
  • Language: English
  • Identifier: ISSN: 1710-1492
    ISSN: 1710-1484
    EISSN: 1710-1492
    DOI: 10.1186/s13223-023-00845-9
  • Source: GFMER Free Medical Journals
    PubMed Central
    Alma/SFX Local Collection
    Springer Open Access Journals
    Coronavirus Research Database
    ProQuest Central
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait